MYELODYSPLASTIC SYNDROMES
Clinical trials for MYELODYSPLASTIC SYNDROMES explained in plain language.
Never miss a new study
Get alerted when new MYELODYSPLASTIC SYNDROMES trials appear
Sign up with your email to follow new studies for MYELODYSPLASTIC SYNDROMES, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for hard-to-treat blood cancers? early trial tests DSP107 combo
Disease control TerminatedThis early-phase study tested a new drug called DSP107 combined with standard chemotherapy for people with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML) that had come back or not responded to prior treatments. The goal was…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Kahr Medical • Aim: Disease control
Last updated May 01, 2026 15:28 UTC
-
Early-Stage drug combo study for MDS halted
Disease control TerminatedThis study tested combinations of drugs in 33 adults with lower-risk myelodysplastic syndrome (MDS), a blood disorder. The goal was to find safe doses and understand side effects. The study was terminated early, so results are limited.
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 01, 2026 15:27 UTC
-
Experimental MDS drug combo shows promise but study halted early
Disease control TerminatedThis study tested adding an experimental drug (MBG453) to standard chemotherapy for people with a serious bone marrow disorder called myelodysplastic syndrome (MDS). The goal was to see if the combination could improve remission rates and delay disease progression. The study incl…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated May 01, 2026 15:24 UTC
-
Experimental combo for MDS/AML shows early safety data
Disease control TerminatedThis early-phase trial tested a new drug called SL-172154, given with standard chemotherapy drugs (azacitidine with or without venetoclax), in adults with higher-risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The study aimed to find a safe dose and check for…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Shattuck Labs, Inc. • Aim: Disease control
Last updated Apr 30, 2026 15:50 UTC
-
Immune cell therapy shows promise for tough leukemia cases
Disease control TerminatedThis study tested a treatment called TCB008 for people with acute myeloid leukemia (AML) that came back or didn't respond to standard therapy. TCB008 uses donor immune cells (gamma-delta T cells) grown in a lab to attack the cancer. The trial aimed to see if these cells could red…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE2 • Sponsor: TC Biopharm • Aim: Disease control
Last updated Apr 30, 2026 15:49 UTC
-
Experimental stem cell shot aims to stop transplant rejection in blood cancer patients
Disease control TerminatedThis early-stage study tested whether giving patients a special type of stem cell (called interferon gamma-primed mesenchymal stromal cells) around the time of a bone marrow transplant could safely prevent graft-versus-host disease, a serious complication where donor cells attack…
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: Edwin Horwitz • Aim: Disease control
Last updated Apr 29, 2026 15:01 UTC
-
Early study comparing oral and IV cladribine stopped after just 3 patients
Knowledge-focused TerminatedThis study aimed to see if an oral form of the drug cladribine works similarly to the standard IV form in people with certain blood cancers like leukemia. Only 3 adults took part before the study was stopped early. The main goal was to check safety and how the drug moves through …
Matched conditions: MYELODYSPLASTIC SYNDROMES
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Apr 30, 2026 15:52 UTC